Lightnews — Scholar-powered news

GHF Ph.D ErCLG (EBMG)

@ghf.bsky.social

520 followers 180 following 8 posts

Dad. Husband. Cinical scientist cancer genomics - solid tumours and post-hsct monitoring. 🏴󠁧󠁢󠁳󠁣󠁴󠁿

Posts Replies Media Videos

Reposted by GHF Ph.D ErCLG (EBMG)

Gregory Riely

@rielymd.bsky.social

Paper on sunvozertinib in EGFR exon 20 insertions out in @ASCO JCO. 46% response rate for 200 mg dose. Now FDA approved, but can't seem to get the drug for patients ascopubs.org/doi/full/10....

ASCO Publications

ascopubs.org

September 22, 2025 at 9:20 PM

GHF Ph.D ErCLG (EBMG)

@ghf.bsky.social

Hello! I am doing this tomorrow #tourde4 any donations for MacMillan cancer care gratefully received 👌🏼

gofund.me/50eb53a4f

Donate to My Tour De 4 Fundraiser to Fight Cancer, organized by Gordon Forbes

Want to join me in supporting a good cause? I'm raising money for Macmillan Canc… Gordon Forbes needs your support for My Tour De 4 Fundraiser to Fight Cancer

gofund.me

September 6, 2025 at 9:50 AM

Reposted by GHF Ph.D ErCLG (EBMG)

Brittany Harvey

@brittanyeharvey.bsky.social

New rapid recommendation update on systemic therapy for small-cell lung cancer from ASCO just published: ascopubs.org/doi/full/10.... #ASCOguidelines #MedSky #OncSky #LCSM

Visual abstract for Systemic Therapy for SCLC Rapid Guideline Update:
2.4. Patients with LS-SCLC who have completed concurrent chemoradiotherapy and do not have disease progression should be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy. (Evidence quality: Moderate; Strength of recommendation: Strong)

5.3.1. Patients with LS-SCLC and ECOG PS 3-4 due to SCLC who have been treated with concurrent or sequential chemotherapy and radiotherapy may be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy and there is improvement in PS. (Evidence quality: Low; Strength of recommendation: Conditional)

4.1. In patients with relapsed SCLC with a chemotherapy-free interval of less than 90 days, single-agent systemic therapy may be offered. Preferred agents are topotecan, lurbinectedin or tarlatamab. (Evidence quality: Moderate; Strength of recommendation: Strong)

4.2. In patients with relapsed SCLC with a chemotherapy-free interval of at least 90 days, re-challenge with a platinum-based regimen or single-agent chemotherapy (preferred agents are topotecan, lurbinectedin or tarlatamab) may be offered. (Evidence quality: Moderate; Strength of recommendation: Strong)

Kalemkerian et al J Clin Oncol 2024
asco.org/thoracic-cancer-guidelines

November 20, 2024 at 9:39 PM

Reposted by GHF Ph.D ErCLG (EBMG)

Nathan Pennell MD, PhD, FASCO

@n8pennell.bsky.social

How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/... #LCSM

How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice

Until the early 2000s, advanced or metastatic non–small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the ...

ascopubs.org

November 18, 2024 at 12:38 PM

Reposted by GHF Ph.D ErCLG (EBMG)

Vivek Subbiah, MD

@viveksubbiah.bsky.social

🚨🥁🔔 Hot off the press! 🔔
We are thrilled to share our latest editorial in journal Annals of #Oncology 👉"The Best Management for Most Patients with Incurable Cancer is on a Clinical Trial."
#medtwitter #ClinicalTrials
www.annalsofoncology.org/article/S092...

DEFINE_ME

www.annalsofoncology.org

November 16, 2024 at 12:59 AM